Document is current
Any future updates will be listed below
-
Authors
Ort, Jordan T. https://orcid.org/0000-0001-6977-4168
Sobel Leonard, Ashley
Li, Shuk Hang https://orcid.org/0000-0001-8462-6657
Atkinson, Reilly K. https://orcid.org/0009-0003-9519-5700
Mendoza, Lydia M. https://orcid.org/0000-0002-6522-0501
Vieira, Marcos Costa https://orcid.org/0000-0002-6731-4202
Gang, Sydney https://orcid.org/0000-0003-0410-7262
Cobey, Sarah https://orcid.org/0000-0001-5298-8979
Hensley, Scott E. https://orcid.org/0000-0002-2928-7506
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (75N93021C00015)
U.S. Department of Health & Human Services | National Institutes of Health (R01AI08686)
- License Information
-
More Information
Article History
Received: 8 September 2025
Accepted: 28 April 2026
First Online: 11 May 2026
Competing interests
: S.E.H. is a co-inventor on patents that describe the use of nucleoside-modified mRNA as a vaccine platform. S.E.H reports receiving consulting fees from Sanofi, Pfizer, Lumen, Novavax, and Merck. A.S.L. is now an employee of Sanofi but was affiliated with the Children’s Hospital of Pennsylvania when this work was completed. The authors declare no other competing interests.
